Focus shifted to development of first tri-specific antibody from the CAPTN-3 platform, IM1240, targeting 5T4 tumor-associated antigen, and second tri-specific antibody, IM1305, named as development candidate, targeting TROP2  Achieved toxicology and manufacturing milestones for IM1240, demonstrating an expanded therapeutic window and commercially viable yield Positive preclinical data presented at ESMO Immuno-Oncology Congress 2025 demonstrates multi-arm anti-tumor activity for both IM1240 and IM1305 Total Cash Position of $9.5 million as of December 31, 2025, expected to provide runway into 2027 REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed...

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to create a differentiated company focusing on clinical metabolic and autoimmune pipeline assets and to build on the Company’s base of high caliber institutional investors, expected to complete in the second quarter of 2026 Multiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026GERMANTOWN, Md., March 13, 2026 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the year ended December 31, 2025, and provided an overview of the Company’s corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune...

GRAND CAYMAN, Cayman Islands, March 13, 2026 (GLOBE NEWSWIRE) — Activate Energy Acquisition Corp. (NASDAQ: AEAQ) (the “Company”), a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, today announced that it has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). Key Highlights from the Annual Report Include:Cash and Investments: Approximately $ 230,556,356 held in the trust account, invested in U.S. government securities or money market funds meeting certain conditions under Rule 2a-7 of the Investment Company Act.Operating Results: Net income of $ 300,371...

FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing of its credit facility. As a result, the Company enters 2026 with a strong foundation for successful growth LONDON, March 13, 2026 (GLOBE NEWSWIRE) —...

FY25 results webcast to take place on Friday, 27 March 2026 at 3pm CET Louvain-la-Neuve, Belgium, 13 March 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the full year 2025 on Friday, 27 March 2026 at 7am CET. Conference Call Information IBA’s management team will host team will host a conference call and webcast conducted in English to present the half year results, followed by a Q&A session. The conference call will be held on Friday, 27 March 2026 at 3pm CET / 2pm BST / 10am EDT / 7am PDT as a Teams webinar. To attend the webcast, register via this link. The presentation will be available on IBA’s investor relations website and on: https://www.iba-worldwide.com/iba-full-year-2025-results-press-release-conference-call...

Kyivstar Group Ltd (“Kyivstar,” the “Group”) FY25 and 4Q25 results highlightsTotal revenue for FY25 grew 25.9% to USD 1,157 mn (30.3% to UAH 48.2 bn) year-on-year (“YoY”). 4Q25 revenue increased 28.4% to USD 321 mn (30.1% to UAH 13.5 bn) YoY. EBITDA for FY25 rose 25.8% to USD 648 mn (30.0% to UAH 27.0 bn) with an EBITDA margin of 56.0%. In 4Q25, EBITDA increased 21.7% to USD 172 mn (23.1% YoY to UAH 7.2 bn) with the EBITDA margin at 53.5%. Adjusted net profit was USD 289 mn for FY25, with earnings per share of USD 1.32. Unadjusted net profit was USD 124 mn, EPS USD 0.57, the differences from adjusted numbers resulting from the USD 162 mn non-cash charge related to the Kyivstar listing in 3Q25. Unadjusted net profit for 4Q25 was USD 90 mn. Digital revenue grew 4.7x in FY25 to USD 124 mn (4.9x to UAH 5.2 bn), reaching 10.7% of the revenue...

VEON Delivers Record Digital Growth: 4Q25 Digital Revenues Grow 84% to 20.1% of Total, Driving 17% Revenue and 29% EBITDA Growth in 4Q25 Dubai and New York, March 13, 2026 – VEON Ltd. (NASDAQ: VEON), a global digital operator, today announced strong financial and operating results for the fourth quarter and full year ended December 31, 2025. Key Highlights – Fourth Quarter 2025Total revenue grew 17.4% year-on-year (“YoY”) to USD 1,171 million. EBITDA increased 29.1% YoY to USD 527 million, with EBITDA margin expanding 410 bps to 45.0%. Digital revenues grew 84.1% YoY to USD 235 million, accounting for 20.1% of Group revenue. Financial services revenues rose 28.1% YoY to USD 120 million.Key Highlights – Full Year 2025Total revenue increased 9.9% YoY to USD 4,399 million. EBITDA rose 18.8% YoY to USD 2,009 million, with EBITDA margin...

VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) — Tree Island Steel (“Tree Island” or the “Company”) (TSX: TSL) today reported its financial results for the year ended December 31, 2025. For the three-month period ended December 31, 2025, revenues, net of freight and distribution, were $32.4 million, compared with $44.8 million in the same period last year. The decline primarily reflected lower U.S. sales volumes due to the ongoing impact of expanded U.S. tariffs on wire and wire products, as well as the Company’s strategic withdrawal from certain unprofitable product lines. These factors were partially offset by continued growth in Canadian sales, consistent with the Company’s increased focus on domestic markets. For the full year, revenues totaled $161.8 million, down from $207.0 million in 2024. Despite higher average...

TORONTO, March 12, 2026 (GLOBE NEWSWIRE) — Firm Capital Mortgage Investment Corporation (the “Corporation”) (TSX FC, FC.DB.J, FC.DB.K ,FC.DB.L and FC.DB.M) today released its financial statements for the three and twelve months ended December 31, 2025. NET INCOME For the three months ended December 31, 2025, net income decreased by 4.7% to $8,735,874 as compared to $9,164,362 for the same period in 2024. Net income for the year ended December 31, 2025, increased by 6.4% to $37,471,563, as compared to $35,228,450 reported for the same period in 2024. EARNINGS PER SHARE Basic weighted average earnings per share for the three months ended December 31, 2025 was $0.238, as compared to the $0.249 per share reported for the three months ended December 31, 2024. Basic weighted average earnings per share for the year ended December 31, 2025...

VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2025. All dollar values are in U.S. dollars unless stated otherwise. “2025 was a pivotal year for Eupraxia. We achieved significant clinical milestones in the development of our lead program, EP-104GI, and strengthened our balance sheet with two recent financings, positioning us well for our next phase of growth” said James Helliwell, CEO of Eupraxia. “As we look ahead to an exciting year, we anticipate multiple clinical readouts...